by Casey Hall for Reuters

“CanSino Biologics (6185.HK) has agreed with AstraZeneca (AZN.L) to provide ‘contract development and manufacturing services’ to support the Anglo-Swedish drugmaker’s messenger RNA (mRNA) vaccine programme, the Chinese company said on Tuesday.

In a filing to Shanghai’s stock exchange, CanSino said it would manufacture and supply unspecified mRNA products to AstraZeneca. It did not disclose the value of the deal.

AstraZeneca said the deal would support investigational mRNA vaccines in its early pipeline.

‘AstraZeneca is working on next-generation technologies to develop vaccines and monoclonal antibodies for infectious diseases where there is high unmet need,; the company said, adding it would share more details as the candidates progress…”

Continue reading at the original source, linked here.